Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Nat Biomed Eng. 2022 Aug 8;6(11):1284–1297. doi: 10.1038/s41551-022-00915-0

Fig. 7. TRAC-1XX-iT cells cure systemic NALM6 tumour model without inducing graft-versus-host disease.

Fig. 7.

a, Schematic representation of systemic NALM6 tumour model. b, Tumour burden (total flux in photons per second) of NALM6-bearing untreated mice (n = 4), or mice treated with 4×106 CD8 TRAC-1XX (n = 5) or TRAC-1XX-iT cells (n = 7, line = one mouse). c, Kaplan-Meier analysis of tumour-free survival (left) and overall survival (right). d, Flow cytometric quantification of tumour cells (left) and T cells (right) in bone marrow 12 days after T cell infusion (n = 2–3 mice). e, Phenotype of persisting TRAC-1XX-iT cells prior to infusion (day 0, n = 1) and of cells derived from the bone marrow on day 6 and 12 days after TRAC-1XX-iT cell infusion (n = 3 mice). * P<0.05, ** P<0.01, *** P<0.001, log-rank Mantel-Cox test (c), Welch’s 2-sample two-sided t test (d). All data are means ± s.d.